Pomalyst already crushing kyprolis even though its been on the market for much less time $AMGN is happy they reported before $CELG...— Ian Estepan (@ianestepan) October 24, 2013Kyprolis is the multiple myeloma drug acquired by Amgen (AMGN - Get Report) in the $10 billion Onyx Pharmaceuticals deal. Both Kyprolis and Pomalyst are approved to treat patients with multiple myeloma that no longer responds to other drugs. In other words, the two drugs compete for the same multiple myeloma patients, but so far, doctors seem to prefer Pomalyst over Kyprolis. Kyprolis sales in the third quarter: $65 million, a touch weaker than Wall Street consensus. The $90 million in Pomalyst sales for the third quarter trounced Wall Street expectations by $16 million, according to JP Morgan analyst Geoff Meacham. Pomalyst is approved in the U.S. and Europe while Kyprolis is sold only stateside, but even Pomalyst U.S. sales of $77 million in the September quarter beat Kyprolis by a comfortable margin. As Estepan points outs, Kyprolis received FDA approval in July 2012 while Pomalyst was approved this past February (European approval came in August.) With less time on the market, Pomalyst is beating its closest competitor, which bodes well for Celgene as the company seeks to expand the drug's use into earlier stage multiple myeloma patients. -- Reported by Adam Feuerstein in Boston. Follow @AdamFeuerstein
Celgene's New Multiple Myeloma Drug Is Kicking Amgen's Ass
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.